Top Page
Aytu BioScience
(NASDAQ:AYTU)
Aytu BioScience (AYTU) vs. SPDR S&P 500 ETF (SPY)
Aytu BioScience Business Overview & Revenue Model
Aytu BioScience Earnings Call Summary
Aytu BioScience Financial Statement Overview
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 69.22M | 81.00M | 107.40M | 96.67M | 65.63M | 27.63M |
| Gross Profit | 47.48M | 49.37M | 66.63M | 46.44M | 29.20M | 20.08M |
| EBITDA | 3.16M | -1.01M | -3.27M | -98.74M | -29.04M | -12.21M |
| Net Income | 1.64M | -15.84M | -17.05M | -108.78M | -58.29M | -13.62M |
Balance Sheet | ||||||
| Total Assets | 124.20M | 118.09M | 136.46M | 137.62M | 265.67M | 152.84M |
| Cash, Cash Equivalents and Short-Term Investments | 18.17M | 20.01M | 22.98M | 19.36M | 49.65M | 48.08M |
| Total Debt | 1.86M | 16.42M | 18.45M | 18.19M | 28.35M | 2.01M |
| Total Liabilities | 89.30M | 90.38M | 97.11M | 93.31M | 128.10M | 57.82M |
| Stockholders Equity | 34.90M | 27.72M | 39.36M | 44.31M | 137.57M | 95.02M |
Cash Flow | ||||||
| Free Cash Flow | -5.74M | -1.39M | -5.13M | -28.82M | -28.30M | -28.37M |
| Operating Cash Flow | -5.53M | -1.39M | -5.13M | -28.82M | -25.96M | -28.37M |
| Investing Cash Flow | 423.00K | -329.00K | -117.00K | -3.25M | -2.78M | -5.66M |
| Financing Cash Flow | 3.52M | -1.26M | 8.87M | 1.53M | 30.31M | 71.07M |
Aytu BioScience Technical Analysis
Aytu BioScience Risk Analysis
Aytu BioScience Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
65 Neutral | $13.88M | ― | 3.29% | ― | -26.17% | ― | |
51 Neutral | $7.95B | -0.40 | -41.67% | 2.21% | 22.29% | -1.85% | |
47 Neutral | $12.50M | ― | -1.98% | ― | 156.93% | 92.75% | |
46 Neutral | $19.61M | ― | -52.69% | ― | ― | ― | |
45 Neutral | $59.31M | ― | -291.74% | ― | -62.57% | 11.60% | |
39 Underperform | $12.68M | ― | -230.73% | ― | -24.10% | 38.17% | |
| ― | $9.06M | ― | ― | ― | ― |
Aytu BioScience Corporate Events
On June 20, 2025, Aytu BioPharma, Inc. expanded and extended its lending agreement with Eclipse Business Capital LLC to provide added working capital flexibility in anticipation of the commercial launch of EXXUA™ in late 2025. This agreement includes extending the term loan maturity to June 2029, increasing the principal balance to $13.0 million, and expanding the revolving credit facility by $1.5 million. EXXUA, a novel antidepressant, is expected to enter the over $22 billion U.S. prescription MDD market, addressing significant unmet needs due to its favorable side effect profile demonstrated in clinical trials.
The most recent analyst rating on (AYTU) stock is a Buy with a $8.00 price target. To see the full list of analyst forecasts on Aytu BioScience stock, see the AYTU Stock Forecast page.
On June 9, 2025, Aytu BioPharma announced the closing of an upsized at-the-market public offering of common stock, raising gross proceeds of $16.6 million. The funds are intended to support the commercialization of EXXUA™, a novel FDA-approved treatment for major depressive disorder, which is expected to launch in the fourth quarter of 2025. This strategic move positions Aytu to enter the $22 billion U.S. prescription MDD market, with EXXUA expected to be a significant growth driver due to its unique mechanism and favorable side effect profile.
The most recent analyst rating on (AYTU) stock is a Buy with a $8.00 price target. To see the full list of analyst forecasts on Aytu BioScience stock, see the AYTU Stock Forecast page.
On June 5, 2025, Aytu BioPharma entered an Exclusive Commercialization Agreement with Fabre-Kramer Holdings to commercialize EXXUA™ (gepirone) extended-release tablets in the United States. EXXUA, an FDA-approved treatment for major depressive disorder (MDD), is expected to launch in the fourth quarter of 2025. The agreement involves a series of financial commitments, including upfront and milestone payments, royalties, and a supply price based on net sales. EXXUA is anticipated to be a significant growth catalyst for Aytu, addressing unmet needs in the $22 billion US prescription MDD market. The product is distinguished by its novel mechanism and lack of sexual dysfunction side effects, positioning it as a transformative option for over 21 million Americans affected by MDD.
The most recent analyst rating on (AYTU) stock is a Buy with a $8.00 price target. To see the full list of analyst forecasts on Aytu BioScience stock, see the AYTU Stock Forecast page.
On June 5, 2025, Aytu BioPharma announced an underwriting agreement with Lake Street Capital Markets for a public offering of common stock and prefunded warrants, aiming to raise approximately $12.9 million. The proceeds will be used for general corporate purposes and to commercialize EXXUA™ (gepirone) extended-release tablets. The offering, expected to close around June 9, 2025, is part of Aytu’s strategy to strengthen its market position in novel therapeutics for major depressive disorder.
The most recent analyst rating on (AYTU) stock is a Buy with a $8.00 price target. To see the full list of analyst forecasts on Aytu BioScience stock, see the AYTU Stock Forecast page.
On May 21, 2025, Aytu BioScience held its 2025 Annual Meeting, where approximately 70% of the company’s common stockholders participated. During the meeting, all incumbent directors were reelected, an amendment to increase shares under the 2023 Equity Incentive Plan was approved, Grant Thornton LLP was ratified as the independent accounting firm, and executive compensation was endorsed through a non-binding advisory vote.
The most recent analyst rating on (AYTU) stock is a Buy with a $8.00 price target. To see the full list of analyst forecasts on Aytu BioScience stock, see the AYTU Stock Forecast page.